Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin

Abstract Calcineurin inhibitors (CNIs) are immunosuppressive drugs used to prevent graft rejection after organ transplant. Common side effects include renal magnesium wasting and hypomagnesemia, which may contribute to new‐onset diabetes mellitus, and hypercalciuria, which may contribute to post‐tra...

Full description

Bibliographic Details
Main Authors: Brittany D. K. Gratreak, Elizabeth A. Swanson, Rebecca A. Lazelle, Sabina K. Jelen, Joost Hoenderop, René J. Bindels, Chao‐Ling Yang, David H. Ellison
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Physiological Reports
Subjects:
Online Access:https://doi.org/10.14814/phy2.14316
id doaj-d55dbaee735b461abbb55adc4a2ef5aa
record_format Article
spelling doaj-d55dbaee735b461abbb55adc4a2ef5aa2020-11-25T03:29:38ZengWileyPhysiological Reports2051-817X2020-01-0181n/an/a10.14814/phy2.14316Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurinBrittany D. K. Gratreak0Elizabeth A. Swanson1Rebecca A. Lazelle2Sabina K. Jelen3Joost Hoenderop4René J. Bindels5Chao‐Ling Yang6David H. Ellison7Division of Nephrology and Hypertension Department of Medicine Oregon Health and Science University Portland OR USADivision of Nephrology and Hypertension Department of Medicine Oregon Health and Science University Portland OR USADivision of Nephrology and Hypertension Department of Medicine Oregon Health and Science University Portland OR USARadboud Institute for Molecular Life Sciences Radboud University Medical Center Nijmegen NetherlandsRadboud Institute for Molecular Life Sciences Radboud University Medical Center Nijmegen NetherlandsRadboud Institute for Molecular Life Sciences Radboud University Medical Center Nijmegen NetherlandsDivision of Nephrology and Hypertension Department of Medicine Oregon Health and Science University Portland OR USADivision of Nephrology and Hypertension Department of Medicine Oregon Health and Science University Portland OR USAAbstract Calcineurin inhibitors (CNIs) are immunosuppressive drugs used to prevent graft rejection after organ transplant. Common side effects include renal magnesium wasting and hypomagnesemia, which may contribute to new‐onset diabetes mellitus, and hypercalciuria, which may contribute to post‐transplant osteoporosis. Previous work suggested that CNIs reduce the abundance of key divalent cation transport proteins, expressed along the distal convoluted tubule, causing renal magnesium and calcium wasting. It has not been clear, however, whether these effects are specific for the distal convoluted tubule, and whether these represent off‐target toxic drug effects, or result from inhibition of calcineurin. The CNI tacrolimus can inhibit calcineurin only when it binds with the immunophilin, FKBP12; we previously generated mice in which FKBP12 could be deleted along the nephron, to test whether calcineurin inhibition is involved, these mice are normal at baseline. Here, we confirmed that tacrolimus‐treated control mice developed hypomagnesemia and urinary calcium wasting, with decreased protein and mRNA abundance of key magnesium and calcium transport proteins (NCX‐1 and Calbindin‐D28k). However, qPCR also showed decreased mRNA expression of NCX‐1 and Calbindin‐D28k, and TRPM6. In contrast, KS‐FKBP12−/− mice treated with tacrolimus were completely protected from these effects. These results indicate that tacrolimus affects calcium and magnesium transport along the distal convoluted tubule and strongly suggests that inhibition of the phosphatase, calcineurin, is directly involved.https://doi.org/10.14814/phy2.14316calcineurin inhibitorcalciumdistal tubulemagnesiumtacrolimus
collection DOAJ
language English
format Article
sources DOAJ
author Brittany D. K. Gratreak
Elizabeth A. Swanson
Rebecca A. Lazelle
Sabina K. Jelen
Joost Hoenderop
René J. Bindels
Chao‐Ling Yang
David H. Ellison
spellingShingle Brittany D. K. Gratreak
Elizabeth A. Swanson
Rebecca A. Lazelle
Sabina K. Jelen
Joost Hoenderop
René J. Bindels
Chao‐Ling Yang
David H. Ellison
Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
Physiological Reports
calcineurin inhibitor
calcium
distal tubule
magnesium
tacrolimus
author_facet Brittany D. K. Gratreak
Elizabeth A. Swanson
Rebecca A. Lazelle
Sabina K. Jelen
Joost Hoenderop
René J. Bindels
Chao‐Ling Yang
David H. Ellison
author_sort Brittany D. K. Gratreak
title Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
title_short Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
title_full Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
title_fullStr Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
title_full_unstemmed Tacrolimus‐induced hypomagnesemia and hypercalciuria requires FKBP12 suggesting a role for calcineurin
title_sort tacrolimus‐induced hypomagnesemia and hypercalciuria requires fkbp12 suggesting a role for calcineurin
publisher Wiley
series Physiological Reports
issn 2051-817X
publishDate 2020-01-01
description Abstract Calcineurin inhibitors (CNIs) are immunosuppressive drugs used to prevent graft rejection after organ transplant. Common side effects include renal magnesium wasting and hypomagnesemia, which may contribute to new‐onset diabetes mellitus, and hypercalciuria, which may contribute to post‐transplant osteoporosis. Previous work suggested that CNIs reduce the abundance of key divalent cation transport proteins, expressed along the distal convoluted tubule, causing renal magnesium and calcium wasting. It has not been clear, however, whether these effects are specific for the distal convoluted tubule, and whether these represent off‐target toxic drug effects, or result from inhibition of calcineurin. The CNI tacrolimus can inhibit calcineurin only when it binds with the immunophilin, FKBP12; we previously generated mice in which FKBP12 could be deleted along the nephron, to test whether calcineurin inhibition is involved, these mice are normal at baseline. Here, we confirmed that tacrolimus‐treated control mice developed hypomagnesemia and urinary calcium wasting, with decreased protein and mRNA abundance of key magnesium and calcium transport proteins (NCX‐1 and Calbindin‐D28k). However, qPCR also showed decreased mRNA expression of NCX‐1 and Calbindin‐D28k, and TRPM6. In contrast, KS‐FKBP12−/− mice treated with tacrolimus were completely protected from these effects. These results indicate that tacrolimus affects calcium and magnesium transport along the distal convoluted tubule and strongly suggests that inhibition of the phosphatase, calcineurin, is directly involved.
topic calcineurin inhibitor
calcium
distal tubule
magnesium
tacrolimus
url https://doi.org/10.14814/phy2.14316
work_keys_str_mv AT brittanydkgratreak tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT elizabethaswanson tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT rebeccaalazelle tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT sabinakjelen tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT joosthoenderop tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT renejbindels tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT chaolingyang tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
AT davidhellison tacrolimusinducedhypomagnesemiaandhypercalciuriarequiresfkbp12suggestingaroleforcalcineurin
_version_ 1724578046375100416